Interpret the correct usage and dosage of the new drug cobimetinib

Cobimetinib, trade name Cotellic, is an oral inhibitor targeting MEK kinase and is mainly used to treat malignant tumors with specific gene mutations. Its primary indication is in combination with Vemurafenib (Vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. In addition, cobimetinib can also be used alone to treat certain histiocytic tumors. Before use, genetic testing must be performed to confirm whether the patient's tumor has the BRAF V600E or V600K mutation to ensure the suitability of the drug.

The standard recommended dose of cobimetinib is once a day, 60mg each time, with 28 days as a treatment cycle, that is, continuous administration for 21 days and then discontinuation of 7 days. This intermittent dosing helps reduce the cumulative toxicity of the drug while maintaining therapeutic efficacy. Cobimetinib can be taken with food or on an empty stomach, but care should be taken to avoid missing doses. If a patient misses a dose or vomits after taking the dose, the patient should not take a missed dose but should continue with the next dose as originally planned. If serious adverse reactions occur, doctors may adjust the dose or suspend treatment to balance efficacy and safety.

Cobimetinib was approved for marketing in the United States and Europe in November 2015, but has not yet been launched in China. There are mainly European and Turkish versions of the original drug in overseas markets, and the specifications are usually 20mg*63 tablets. The price of the European version is higher, about more than 40,000 yuan, while the price of the Turkish version is relatively low, about more than 10,000 yuan. Since the drug has not yet been included in domestic medical insurance and no generic drugs are on the market, patients who want to use it usually need to purchase it through formal cross-border medical consulting agencies and pay attention to the legality and safety of the drug.

In general, cobimetinib is an effective treatment for tumors with specific genetic mutations, but it is relatively expensive and must be used strictly according to medical instructions. Patients should regularly monitor the efficacy and adverse reactions during medication, and adjust the treatment plan under the guidance of a doctor to ensure the best treatment effect.

Reference link:https://www.gene.com/patients/medicines/cotellic